Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07303101

One-stage Exchange in Candida Periprosthetic Infection a Suitable Way to go

Status
Recruiting
Phase
Study type
Observational
Enrollment
16 (estimated)
Sponsor
University Hospital, Strasbourg, France · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Accounting for only 0.7% to 3% of joint prosthesis infections, yeast infections are considered particularly difficult to treat. They are primarily caused by Candida yeasts, representing over 90% of cases. Surgical treatment is the cornerstone of managing periprosthetic infections. In cases of chronic bacterial infections, complete implant replacement is necessary and can be performed either in one or two stages. However, for chronic Candida spp. infections, two-stage prosthesis replacement remains the preferred option. Only three retrospective, single-center studies have evaluated the success rate of one-stage prosthesis replacement in periprosthetic Candida spp. infections in selected patients. Although the sample sizes of these studies are small, the 2-year success rate of 63% to 81% differs little from that of two-stage implant replacement (47% to 100%). Furthermore, systemic antifungal treatment is poorly defined. Recommendations are based on studies with a low level of evidence. The hypothesis is that a single-stage prosthesis replacement combined with appropriate antifungal treatment for chronic periprosthetic Candida spp. infection has the same outcome as a two-stage prosthesis replacement.

Conditions

Timeline

Start date
2025-05-28
Primary completion
2026-02-01
Completion
2026-02-01
First posted
2025-12-24
Last updated
2025-12-24

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT07303101. Inclusion in this directory is not an endorsement.

One-stage Exchange in Candida Periprosthetic Infection a Suitable Way to go (NCT07303101) · Clinical Trials Directory